Zurich, Switzerland
Leading Lupin Atlantis Holdings SA's EMEA operations, my focus lies in steering international business strategy and expansion, having successfully launched multiple pharmaceutical products across diverse markets. With a proven track record in general management, our teams have driven substantial growth and established a robust network of affiliates, demonstrating agility and innovation in a dynamic industry landscape. At the helm of complex operations, we've excelled in market access and product launches, while also fostering strategic partnerships and M&A activities. The pursuit of operational excellence and a patient-centric approach underpin our endeavors, ensuring our contributions not only elevate our organization but also reinforce the industry's reputation for quality and integrity.
International Operations Management of Galenica Group Pharma Division, with 640 MCHF turnover and 750 Headcounts. Executive Committee Member, reporting to the Galenica CEO -In charge of all the Worldwide operations with a network of 14 Affiliates and 7 regional offices. -Managed a complex portfolio of Rx,OTx and Consumer Brands and licenced products with own organisations and Partners -Set-up of Affiliates (14 to date) and Regional organisations (7) for both Rx Vifor and OM Pharma and Consumer Healthcare internationally -Launch of our major product Ferinject in more than 50 countries to date
Management of the Swiss pharma branch of the Galenica Group. Line management responsibility for Sales and Marketing, BD&L, Finance and IT, Medical, Clinical Research, Regulatory, HR, Corporate Affairs, Manufacturing and Quality -200 MCHF turnover and 550 Headcounts, with OTC BU N°3 on Swiss market and Rx sales from 40 MCHF to 100 MCHF Net Sales in 2014 -Development of the OTC portfolio with Affiliate build-up in UK through Company Acquisition of Equazen LTd and business partners in 20 countries worldwide -Launch of Ferinject and Equazen, 2 best launches in 2005 (IMS survey) -Supply Chain turnaround with development of 3rd Party manufacturing -Development of Rx project spin-off with Equazen, faisability study -Ran the Biogen negotiation for 3rd party production, now in place -Conception and implementation of a unique multi-disciplinary approach to create awareness with the 1st Iron Academy
Management of the Swiss affiliate, reporting to the Vice-President EMEA & liaison to the Wyeth Global & EMEA BD&L teams -Leader of a project team, in France, working on a regional Company acquisition -Reporting to the Vice-President EMEA & liaison to the Wyeth Global & EMEA BD&L teams
-Management of the Swiss affiliate with 90 MCHF turnover and 90 collaborators .Reporting to the Vice-President EMEA -In 3 years, Wyeth IMS ranking jumped from 21 to 13, with sales growth + 20% in 2004, and 3 market leading products -In primary care, Effexor launch which soon became N°1 AD -From Biotech, 1st Enbrel launch outside US and 1st Prevenar & Meningitec vaccines launches in Europe with inclusion into list -Active participation as GM in a global Women’s health R&D group on development of a new Menopause product